Jump to content


Photo

TGF- α and IL-6 plasma levels selectively identify CML patients that fail to achieve an early molecular response or progress in the first year of ther


  • Please log in to reply
No replies to this topic

#1 gerry

gerry

    Advanced Member

  • Members
  • PipPipPip
  • 1,034 posts

Posted 24 February 2016 - 07:21 PM

TGF- α and IL-6 plasma levels selectively identify CML patients that fail to achieve an early molecular response or progress in the first year of therapy.

Abstract

Early molecular response (EMR, BCR-ABL1 (IS)⩽10% at 3 months) is a strong predictor of outcome in imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients, but for patients who transform early, 3 months may be too late for effective therapeutic intervention.

http://www.ncbi.nlm....pubmed/26898188




1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users